Full Text View
Tabular View
No Study Results Posted
Related Studies
Double-Blind,Double-Dummy,Effic/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx (LCPTacro3002)
This study is ongoing, but not recruiting participants.
Study NCT01187953   Information provided by Veloxis Pharmaceuticals

First Received on August 23, 2010.   Last Updated on May 25, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Renal Failure
Additional conditions recognized in this trial
Renal Insufficiency
More general conditions related to this trial
Kidney Diseases
Urologic Diseases
Interventions listed in this trial
Prograf (tacrolimus)
LCP-Tacro
Additional drug interventions recognized in this trial
Tacrolimus
More general drug interventions related to this trial
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Veloxis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services